Lung cancer has the highest
morbidity and
mortality among malignant
tumors in our country.The
treatment researches related to
non-small cell lung cancer (NSCLC) such as targeted
therapy and
immunotherapy are the
research hotspots in recent years.
Nivolumab is the first programmed
death-1 (PD-1)inhibitor which is allowed to enter clinical trials,and it is also the first approved
drug for
tumor immunotherapy in
China.In June 2018,
Nivolumab injection was marketed in
China,and it was used in the second-line
treatment for the
patients with advanced NSCLC,opened up a new era of the
lung cancer treatment in our country.
Review the clinical
research related to the
Nivolumab and NSCLC,summarizing usage,
dosage,adverse reactions,
will provide a help for clinical application,bring more benefits for
patients at the same
time.